Neurological
Refine Search
Pharmaceutical
Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with Elanco Animal Health and affiliates for monepantel, the active pharmaceutical ingredient in NUZ-001. 2 July 2025
Pharmaceutical
Mental health company atai Life Sciences was trading more than 31% higher during Tuesday morning’s trading in New York. 1 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD)—including certain formulations of amphetamine and methylphenidate—to warn of the risk of weight loss and other adverse reactions in patients younger than six years. 1 July 2025
Biotechnology
Denmark-based Vesper Bio, a biotech developing an oral therapy for frontotemporal dementia, has announced the appointment of Jacob Falck Hansen as chief executive. 1 July 2025
Pharmaceutical
Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its primary endpoint. However, the company is now pointing to encouraging signs in a subset of patients, which it says could guide future development of its candidate, XPro (pegipanermin). 1 July 2025
Pharmaceutical
US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders, has highlighted The Lancet Psychiatry’s publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). 30 June 2025
Pharmaceutical
Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 billion in 2024. The trend has carried into 2025, with total disclosed acquisitions reaching $16.8 billion by May, according to GlobalData. 30 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Biotechnology
Bayer’s cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and shutting its research labs in Massachusetts to streamline operations and concentrate on advanced-stage programs. 26 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Biotechnology
Psychedelic medicines company Compass Pathways was trading 46% lower midday Monday. 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) has not been recommended for use in the National Health Service (NHS) in England. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Pharmaceutical
Australian neurodegenerative diseases specialist Neurizon Therapeutics has agreed an exclusive global license agreement with Elanco Animal Health and affiliates for monepantel, the active pharmaceutical ingredient in NUZ-001. 2 July 2025
Pharmaceutical
Mental health company atai Life Sciences was trading more than 31% higher during Tuesday morning’s trading in New York. 1 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD)—including certain formulations of amphetamine and methylphenidate—to warn of the risk of weight loss and other adverse reactions in patients younger than six years. 1 July 2025
Biotechnology
Denmark-based Vesper Bio, a biotech developing an oral therapy for frontotemporal dementia, has announced the appointment of Jacob Falck Hansen as chief executive. 1 July 2025
Pharmaceutical
Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its primary endpoint. However, the company is now pointing to encouraging signs in a subset of patients, which it says could guide future development of its candidate, XPro (pegipanermin). 1 July 2025
Pharmaceutical
US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders, has highlighted The Lancet Psychiatry’s publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). 30 June 2025
Pharmaceutical
Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 billion in 2024. The trend has carried into 2025, with total disclosed acquisitions reaching $16.8 billion by May, according to GlobalData. 30 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Biotechnology
Bayer’s cell therapy subsidiary BlueRock Therapeutics is shifting its priorities, cutting around 50 jobs and shutting its research labs in Massachusetts to streamline operations and concentrate on advanced-stage programs. 26 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Biotechnology
Psychedelic medicines company Compass Pathways was trading 46% lower midday Monday. 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) has not been recommended for use in the National Health Service (NHS) in England. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Pharmaceutical
US pharma firm Lisata Therapeutics has teamed up with tech-bio company GATC Health in a strategic alliance aimed at using artificial intelligence to streamline drug development and improve success rates. 18 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze